Keyword: Monsanto

With angry investors and thousands of lawsuits bearing down, Bayer is scrambling to keep its head above water. Looks like relief isn’t coming soon.

More than half of Bayer shareholders gave a thumbs down to executives and their actions in 2018, the lowest approval rating for a German company since World War II.

China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.

Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.

Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report reveals.

A judge struck a large portion of a Roundup verdict against Bayer, but as thousands of lawsuits pile up, the litigation is just getting started.

As Bayer digests its massive Monstanto buyout, its consumer healthcare unit is faltering, but pharma appears to be holding its own.

Bayer’s new billboards in St. Louis depict the iconic Gateway Arch planted in greenery to celebrate the close of the Monsanto acquisition.

Bayer's latest campaign rolls with hometown America to show the company's broad array of products and connections to consumers.